Concord Medical adds two new centers by furthering partnership with Navy General Hospital

Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced that it will add two new centers to its extensive network by furthering its partnership with the PLA Navy General Hospital ("Navy General Hospital" or "the hospital"), located in Beijing.

Concord Medical will add two new centers to the Beijing-based Navy General Hospital's existing facilities, bringing the total number of centers under the Company's management at the hospital to seven. One of the centers will house an Image Guided Radiation Therapy (IGRT) system and the other center will house a Body Gamma Knife system. The IGRT center commenced trial operation in mid June and both centers are expected to enter into full operation in the third quarter of 2010. Prior to these new centers, Concord Medical had been managing five radiotherapy and diagnostic imaging centers at the Navy General Hospital, one of Concord Medical's earliest hospital partners. With the additional centers, the hospital will further strengthen its position to become one of the top cancer treatment facilities in China.

"We are excited to further expand our services at the Navy General Hospital with the addition of two new centers. This expansion underscores our ability to grow with our hospital partners through quality service and effective management, and puts the Navy General Hospital into one of the top cancer treatment facilities in China. In addition, furthering a longstanding partnership symbolizes recognition of the value of our services on top of our financial support to the hospital," said Dr. Jianyu Yang, director, president and chief executive officer of Concord Medical. "Concord Medical is on track to achieve our goal of operating at least 200 centers by 2012. As the industry leader with the largest network of radiotherapy and diagnostic imaging centers in China, we are committed to making cancer treatment more readily available in China and are confident that we are well positioned to benefit from a favorable market environment supported by medical reform policies and increasing consumer demand for world-class cancer treatment."